CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $526,569 | +87369.9% | 11,601 | +8.1% | 0.09% | +71.7% |
Q2 2023 | $602 | +20.9% | 10,731 | -2.6% | 0.05% | +29.3% |
Q1 2023 | $498 | -100.0% | 11,014 | +94.6% | 0.04% | +105.0% |
Q4 2022 | $230,119,650 | +44933.2% | 5,661 | -27.6% | 0.02% | -60.0% |
Q3 2022 | $511,000 | +26.2% | 7,821 | +17.3% | 0.05% | +22.0% |
Q2 2022 | $405,000 | +46.2% | 6,668 | +166.1% | 0.04% | +32.3% |
Q3 2021 | $277,000 | -8.6% | 2,506 | +2.2% | 0.03% | -27.9% |
Q2 2021 | $303,000 | +21.2% | 2,452 | +53.4% | 0.04% | +22.9% |
Q4 2020 | $250,000 | – | 1,598 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |